# Radiopharm Theranostics

Source: https://nuclide.cc/companies/radiopharm-theranostics/  
Nuclide record `radiopharm-theranostics` (Company). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

Radiopharm Theranostics is an Australia-based radiopharmaceutical company that leads 3 cancer trials in Nuclide, testing the radiopharmaceuticals 161Tb-RAD402, 177Lu-BetaBart and the PET tracer RAD101 in prostate cancer, colorectal cancer, non-small-cell lung cancer and ovarian cancer.

## Summary

Radiopharm Theranostics is a clinical-stage company developing radiopharmaceuticals for the diagnosis and treatment of cancer, using nanobody, antibody, small-molecule and peptide platforms directed at targets other than PSMA, FAP and SSTR2. It has a joint venture with MD Anderson Cancer Center and is listed in Australia and on Nasdaq. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in Nuclide: NCT07189871 (phase 1/2, 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Me...), NCT07259213 (phase 1/2, A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC) and NCT06777433 (phase 2, Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Radiopharm Theranostics, Ltd
- Tags: ctgov-sponsor
- HQ: Melbourne
- Type: radiopharma
- Website: https://radiopharmtheranostics.com/
- Ticker: ASX:RAD, NASDAQ:RADX

## Sources

- Official website: https://radiopharmtheranostics.com/
- ClinicalTrials.gov: trials led by Radiopharm Theranostics: https://clinicaltrials.gov/search?lead=Radiopharm%20Theranostics%2C%20Ltd

## Connected records

- isotopes: [Lutetium-177](https://nuclide.cc/isotopes/lu-177/), [Terbium-161](https://nuclide.cc/isotopes/tb-161/)
- indications: [Prostate cancer](https://nuclide.cc/indications/prostate/)
- trials: [177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors](https://nuclide.cc/trials/nct07189871/), [A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC](https://nuclide.cc/trials/nct07259213/), [Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases](https://nuclide.cc/trials/nct06777433/)

---
JSON: https://nuclide.cc/api/v1/entities/radiopharm-theranostics.json